While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > BUSINESS
BUSINESS
- Deloitte Proposal to Shed Number of Generics Aims to Spur Industry Consolidation
December 5, 2022
- Mochida Set to Market Lilly’s Ulcerative Colitis Drug Candidate in Japan
December 5, 2022
- 2 Cancer Meds in PIII, Genmab to Rev Up Rep Hiring to Build Sales Regime in Japan
December 2, 2022
- Twymeeg Tops GP Promotion Ranking for 3 Months Running in September: Intage
December 2, 2022
- Healios to Provide Universal Donor Cells to Sumitomo
December 2, 2022
- Mochida Obtains Japan Marketing Rights for Ferring’s Ulcerative Colitis Drug
December 2, 2022
- Taisho’s Nanozora, 1st Nanobody Agent in Japan, Now Available
December 2, 2022
- AstraZeneca Japan Set to Buttress Respiratory Business with Tezspire Debut
December 2, 2022
- Ultragenyx to Ramp Up Ultra-Orphan Drug Development, Bolster Hiring in Japan
December 1, 2022
- Moderna Inks Digital Transformation Pact with Japanese Health Tech
December 1, 2022
- Novartis Rolls Out Cosentyx 300 mg Pen in Japan
December 1, 2022
- HUYA Japan to Transfer Hiyasta Marketing Authorization to Meiji
December 1, 2022
- Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
December 1, 2022
- Aricept Label Now Modified for Lewy Body Dementia Indication: Eisai
November 30, 2022
- Shionogi Curbs Shipments of Xofluza 10 mg on Big Demand
November 30, 2022
- Parexel Poised to Upsize Japan Workforce by 10%-Plus as Opportunities Expand
November 30, 2022
- SanBio Links Arms with Keio University on Alzheimer’s Drug Research
November 30, 2022
- No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
November 30, 2022
- KM Biologics to File COVID Jab in Japan Spring 2023: Official
November 29, 2022
- Kyowa Kirin Unit, Grunenthal Seal JV Deal for Established Medicines Biz
November 28, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…